The growth lever most small-cap CROs decline.
Therapeutic-area expansion is the highest-value growth lever a small-cap CRO can pull, and the one most decline. The reason is structural: an investigator portfolio that took 14 years to build in adult oncology does not translate into pediatric oncology, and no small-cap CRO can justify a second decade of network-building for a single bid. The lever sits unused because the substrate does not exist internally.
A sponsor relationship they could not afford to lose.
A mid-size biotech sponsor the CRO had served across three adult oncology studies issued a pediatric oncology RFP. The CCO’s default, after declining pediatric for eleven years on the same reason, was to decline again. The CEO overrode it inside 24 hours: we do not walk away from our largest sponsor because our footprint is too shallow.
The real question was not whether they could deliver a pediatric study. It was whether they could produce a bid-credibility package in pediatric oncology inside 21 days. Subcontracting, a bid-partnership, or an 18-month BD hire each failed on margin, timing or account control.
“We declined pediatric for eleven years on the same reason. We stopped declining pediatric when the reason stopped being real.”
Chief Commercial Officer · To be disclosedA global footprint, rented on day one.
The CRO evaluated Yendou Site Graph and Networks against one acceptance test: produce a pediatric oncology investigator layer of 300 or more sites across the sponsor’s target geographies inside two business weeks. Yendou ran the indication against its 90-network, 16,051-investigator global substrate, cross-referenced with the CRO’s eligibility criteria and the sponsor’s protocol. The first-pass qualified portfolio came back in six business days: 418 pediatric oncology investigators across 17 countries, screened for indication experience, prior pediatric-study participation and responsiveness. The RFP response was approved that same week.
The bid defense ran 38 minutes. The sponsor’s VP of Clinical Operations opened with “I did not know you did pediatric.” The CCO’s answer: “We do now.” The award landed two weeks later at €3.2M in service fees, with first-patient-in planned for Q3 2026.
Bid credibility as a renewable resource.
Before the pediatric award, the CRO’s universe was roughly 1,700 oncology investigators, assembled over 14 years. After deployment, the addressable universe is 16,051 investigators across 43 countries and 53 indications, available on day one of any new therapeutic-area expansion. The CRO is extending the footprint into rare-disease and cardiometabolic pediatrics, two indications it had treated as outside its credibility envelope. The year-two commercial plan projects four new therapeutic-area entries with a combined €18M in addressable bid value.
“Our growth strategy used to be constrained by our site network. It is now constrained by our operational judgement. That is the only constraint a CEO actually wants.”
Chief Executive Officer · To be disclosed